Xizang Weixinkang Pharmaceutical Co (SHSE:603676) Inventories, Finished Goods: ¥32 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:603676 Xizang Weixinkang Pharmaceutical Co Ltd SHSE:603676
75 GF Score
Price ¥9.23
GF Value ¥8.70
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Xizang Weixinkang Pharmaceutical Co Inventories, Finished Goods?

Xizang Weixinkang Pharmaceutical Co SHSE:603676 -1.39% 75 Inventories, Finished Goods is ¥32 Mil as of Jun. 2026. GuruFocus rates SHSE:603676 with a GF Score™ of 75/100 and a GF Value™ of ¥8.70 (Fairly Valued). The stock has 3 warning signs investors should review.

Xizang Weixinkang Pharmaceutical Co's quarterly finished goods declined from Dec. 2025 (¥34 Mil) to Mar. 2026 (¥0 Mil) but then increased from Mar. 2026 (¥0 Mil) to Jun. 2026 (¥32 Mil).

Xizang Weixinkang Pharmaceutical Co's annual finished goods increased from Dec. 2023 (¥12 Mil) to Dec. 2024 (¥22 Mil) and increased from Dec. 2024 (¥22 Mil) to Dec. 2025 (¥34 Mil).

Xizang Weixinkang Pharmaceutical Co Inventories, Finished Goods Historical Data

* Premium members only.

The historical data trend for Xizang Weixinkang Pharmaceutical Co's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xizang Weixinkang Pharmaceutical Co Inventories, Finished Goods Chart

Xizang Weixinkang Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventories, Finished Goods
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.92 12.93 12.45 22.34 34.15

Xizang Weixinkang Pharmaceutical Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Inventories, Finished Goods Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.15 0.00 34.15 0.00 31.90
SHSE:603676
75GF Score
Xizang Weixinkang Pharmaceutical Co Ltd SHSE:603676
Inventories, Finished Goods is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Xizang Weixinkang Pharmaceutical Co Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

What does a Inventories, Finished Goods of ¥32 Mil mean?
Xizang Weixinkang Pharmaceutical Co (SHSE:603676) has a Inventories, Finished Goods of ¥32 Mil as of Jun. 2026. Finished goods are inventory items that are complete and ready to be sold. View historical data on Xizang Weixinkang Pharmaceutical Co and its competitors.
Is Xizang Weixinkang Pharmaceutical Co's Inventories, Finished Goods too high?
Xizang Weixinkang Pharmaceutical Co's current Inventories, Finished Goods is ¥32 Mil. Overall, Xizang Weixinkang Pharmaceutical Co has a GF Score™ of 75/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Xizang Weixinkang Pharmaceutical Co's Inventories, Finished Goods compare to ZTS?
Xizang Weixinkang Pharmaceutical Co's Inventories, Finished Goods of ¥32 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Finished Goods for a Drug Manufacturers company?
A good Inventories, Finished Goods depends on the Drug Manufacturers industry context. However, Inventories, Finished Goods should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Finished Goods mean?
A high Inventories, Finished Goods can signal that a stock is expensive relative to its fundamentals. Finished goods are inventory items that are complete and ready to be sold. View historical data on Xizang Weixinkang Pharmaceutical Co and its competitors. Xizang Weixinkang Pharmaceutical Co's current Inventories, Finished Goods is ¥32 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xizang Weixinkang Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Xizang Weixinkang Pharmaceutical Co (SHSE:603676) is currently considered Fairly Valued. The stock's GF Value™ is ¥8.70, compared to a current price of ¥9.23 — trading 6.1% above its estimated fair value. The current Inventories, Finished Goods is ¥32 Mil. Xizang Weixinkang Pharmaceutical Co's overall GF Score™ is 75/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Finished Goods calculated?
Inventories, Finished Goods is calculated from a company's financial statements. For Xizang Weixinkang Pharmaceutical Co (SHSE:603676), the current Inventories, Finished Goods is ¥32 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Xizang Weixinkang Pharmaceutical Co (SHSE:603676) Overvalued in 2026?

Based on GuruFocus' analysis, Xizang Weixinkang Pharmaceutical Co stock appears to be overvalued. The current stock price of ¥9.23 is trading 6.1% above its estimated GF Value™ of ¥8.70. GuruFocus considers Xizang Weixinkang Pharmaceutical Co to be Fairly Valued.

Key valuation signals for SHSE:603676:

  • Inventories, Finished Goods: ¥32 Mil
  • GF Value™: ¥8.70 vs. price of ¥9.23 (6.1% above fair value)
  • GF Score™: 75/100 with 3 warning signs

No single metric tells the full story. See the SHSE:603676 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Xizang Weixinkang Pharmaceutical Co Business Description

Address Yuanqu South Road, 3rd Floor, Building 4, Industrial Center, No. 5, Zone B, Lhasa Economic and Technological, Development Zone, Tibet Autonomous Region, Lhasa, CHN, 850000
Xizang Weixinkang Pharmaceutical Co Ltd is engaged in research & development, production and sales of chemical pharmaceutical preparations and their raw materials. It also produces and sells liver protection drugs and antibiotic products.
75GF Score

Get the complete analysis for SHSE:603676

Inventories, Finished Goods is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥9.23
Price
¥8.70
GF Value